Shopping Cart
Professional article · Diabetic foot disease
PRP for diabetic foot ulcers: evidence, limitations and clinical context
Platelet-rich plasma is being studied as an adjunct for difficult-to-heal diabetic foot ulcers. This article separates PRP from standard care, reviews the evidence and explains when urgent assessment is required.
01
Key points first
Not a diabetes treatment
PRP does not treat diabetes or its underlying cause. Research concerns possible local support of wound healing only.
Standard care comes first
Offloading, debridement, infection control and vascular assessment remain the foundation.
Positive signals, unresolved questions
Meta-analyses report benefits for wound closure and healing time, but protocols and study quality vary considerably.
Not routine treatment
The IWGDF does not recommend routine use of general autologous platelet products. A narrowly defined patch product is assessed separately.
02
What is a diabetic foot ulcer?
A diabetic foot ulcer is an open or deeper wound on the foot of a person with diabetes. Several factors often interact: diabetic neuropathy, repeated pressure, foot deformity, impaired arterial perfusion and an increased risk of infection.
Reduced pain and pressure perception may allow blisters, minor injuries or pressure points to go unnoticed. If peripheral artery disease is also present, less oxygen reaches the tissue. The wound may enlarge, become infected or heal very slowly.
The absence of pain does not rule out serious disease. Wound depth, infection, perfusion and systemic comorbidities require professional assessment.
03
Standard care remains the foundation
A local intervention alone rarely addresses the factors preventing healing. Depending on the findings, structured care includes:
1Relieve pressureEffective offloading reduces ongoing mechanical stress on the ulcer.
2Assess and clean the woundSize, depth and tissue status are documented; non-viable tissue is removed when appropriate.
3Identify infectionLocal or systemic infection may require microbiological testing, antibiotics or surgery.
4Assess perfusionWhen ischaemia is suspected, vascular diagnostics and possible revascularisation must be considered.
5Review progressWound area, exudate, tissue and pressure exposure are reassessed regularly.
PRP cannot replace offloading, treatment of infection or revascularisation. A biologically active dressing cannot reliably close a wound while major barriers to healing remain.
04
What is PRP and why is it being studied?
PRP is plasma derived from autologous blood with a platelet concentration above that of the original blood. After blood collection, components are separated by centrifugation and the intended plasma fraction is processed according to a defined protocol.
Platelets release signalling molecules including PDGF, VEGF and TGF-β. These are involved in cell migration, angiogenesis, granulation tissue formation and other steps of wound healing. This provides biological plausibility, but it does not prove clinical benefit for every ulcer or every PRP system.
PRP is not a single, uniform procedure
The term PRP covers different preparations and delivery methods:
These methods differ in blood volume, centrifugation, platelet concentration, leucocyte content, activation, fibrin structure and treatment interval. Results from one system should not be transferred to another without verification.
05
What does the evidence show?
Randomised trials and meta-analyses report that PRP added to conventional wound care may be associated with more complete wound closures or shorter healing times. Some analyses also report fewer infections or amputations.
These signals are relevant, but they do not support a general success claim. Many trials are small, use different PRP products and include different ulcer stages. Perfusion, infection status, offloading and the quality of standard care are not always comparable or adequately reported.
A larger pooled sample in a meta-analysis does not remove these methodological differences. Certainty therefore remains limited.
Evidence at a glance
Biological plausibilityhigh
Signal for improved closurepresent
Protocol comparabilitylow
Certainty for routine uselimited
06
How does the IWGDF guideline assess PRP?
The 2023 IWGDF wound-healing guideline distinguishes general autologous platelet preparations from a specific autologous leucocyte, platelet and fibrin patch.
General autologous platelet products should not be used routinely in addition to best standard care. The recommendation is conditional and based on low-certainty evidence. Reasons include risk of bias, inconsistent procedures and uncertainty about additional benefit in routine practice.
The specific leucocyte, platelet and fibrin patch may be considered for difficult-to-heal ulcers in selected circumstances. This statement concerns a defined product and must not be generalised to PRP gel, PRP injections or arbitrary preparation systems.
The guideline does not rule out possible benefit. It considers the evidence too uncertain for routine use of general PRP procedures.
07
When might adjunctive use be discussed?
A possible PRP application belongs within a controlled, multidisciplinary treatment plan. At minimum, the following questions should be resolved first:
- Is arterial perfusion adequate?
- Is there a superficial or deep infection?
- Are bone, tendon or joint involved?
- Is the affected area effectively offloaded?
- Has non-viable tissue been appropriately managed?
- How is the wound area changing under current standard care?
There is no universally accepted PRP protocol for diabetic foot ulcers. Blood volume, RCF, runtime, activation, delivery method and intervals must match the system, intended purpose and clinical plan.
08
Risks, limitations and warning signs
Autologous PRP reduces the likelihood of immune reactions to foreign material, but it is not risk-free. Potential issues include blood collection, bleeding, local pain, contamination and hygiene failures. Blood count, coagulation, medication and general health may affect suitability.
Prompt or urgent assessment
- increasing redness, swelling or warmth
- pus, strong odour or markedly increased exudate
- fever, chills or pronounced malaise
- black or necrotic tissue
- a cold, pale or bluish foot
- rapid enlargement or deepening of the wound
- visible tendon, joint or bone
Any open foot wound in a person with diabetes requires timely professional assessment. Infection and ischaemia increase urgency. Neuropathy may mask pain and is not reassuring.
09
Frequently asked questions
Does PRP treat diabetes?
No. PRP does not change the cause of diabetes and does not replace diabetes care. Research addresses possible local support of wound healing only.
Can PRP prevent amputation?
Some studies report lower amputation rates, but this is not a guarantee. Risk depends heavily on ulcer stage, perfusion, infection, offloading and the rest of the treatment plan.
Is PRP gel the same as a PRP injection?
No. Composition, fibrin structure and delivery differ. Results from topical gel should not automatically be applied to perilesional injections.
Is PRP standard treatment for diabetic foot ulcers?
No. Standard care addresses causes, offloading, wound management, infection and perfusion. PRP is being investigated as an adjunct.
What is the correct centrifuge setting?
There is no universal value. Intended purpose, instructions for use, tube, rotor, radius, RCF and the validated protocol of the system are decisive.
10
Clinical perspective
PRP is a biologically plausible and scientifically interesting approach for difficult-to-heal diabetic foot ulcers. Current evidence shows positive signals but remains limited by heterogeneous procedures and methodological weaknesses.
Consistent multidisciplinary standard care remains decisive. Adjunctive use may be discussed in selected cases; qualified clinicians must determine the indication and procedure from the wound status, comorbidities and available evidence.
This professional article provides general information. It does not replace examination, diagnosis, instructions for use, internal SOPs or an individual treatment decision.